Sign Up to like & get recommendations! 1
Published in 2021 at "International Journal of Hematology"
DOI: 10.1007/s12185-021-03092-z
Abstract: Neonatal alloimmune thrombocytopenia (NAIT) arises from fetomaternal platelet incompatibility that results in transplacental passage of maternal antibodies mostly against fetal human platelet antigens (HPA), whereas NAIT due to anti-human leukocyte antigen (HLA) antibodies is extremely… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Thrombosis research"
DOI: 10.1016/s0049-3848(17)30078-6
Abstract: In fetal/neonatal alloimmune thrombocytopenia (FNAIT), platelets are destroyed by maternal antibodies directed against fetal/neonate antigens. Thrombocytopenia can be severe and lead to intracranial hemorrhage (ICH) in about 10% of cases. Although three types of antigen… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "AJP Reports"
DOI: 10.1055/s-0037-1607055
Abstract: Background Treatment for neonatal alloimmune thrombocytopenia (NAIT) primarily involves maternal administration of intravenous immunoglobulin (IVIG) therapy and prednisone according to protocols based on risk stratification. While IVIG is generally well tolerated, hematologic side effects are… read more here.
Sign Up to like & get recommendations! 1
Published in 2018 at "Acta Obstetricia et Gynecologica Scandinavica"
DOI: 10.1111/aogs.13320
Abstract: An important issue on human platelet antigen (HPA)-1a screening has recently been addressed in Acta Obstetrica et Gynecologica Scandinavia. Winkelhorst et al. reported that the vast majority of women in the general pregnant population were positive… read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14385
Abstract: Lack of reliable laboratory parameters is the main challenge in the management of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Despite the long‐known association between the HLA‐DRB3*01:01 allele and human platelet antigen 1a (HPA‐1a) alloimmunisation, maternal… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Paediatrics and Child Health"
DOI: 10.1111/jpc.14735
Abstract: To describe the presenting features and investigation findings in infants diagnosed with neonatal alloimmune neutropaenia (NAIN) within an Australian paediatric health network. The secondary aim was to describe the management and resolution of neutropaenia in… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Transfusion Medicine"
DOI: 10.1111/tme.12892
Abstract: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare life‐threatening disorder, leading to severe thrombocytopenia and potentially bleeding, with intracranial haemorrhage (ICH) being the most serious complication. We report on a FNAIT case with fourth‐degree ICH that… read more here.
Sign Up to like & get recommendations! 1
Published in 2017 at "Transfusion"
DOI: 10.1111/trf.13950
Abstract: Most cases of fetal and neonatal alloimmune thrombocytopenia (FNAIT) are caused by maternal alloantibodies against human platelet antigen‐1a (HPA‐1a). Alloimmunization mainly occurs in HPA‐1a–negative mothers who are carriers of the HLA‐DRB3*01:01 allele. Recently, it has… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Transfusion"
DOI: 10.1111/trf.17342
Abstract: BACKGROUND Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is caused by antibodies against human platelet antigens (HPA). However, in many cases that meet clinical criteria for the condition, maternal sera do not have HPA antibodies. In… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Blood"
DOI: 10.1182/blood.2022015666
Abstract: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a life-threatening bleeding disorder caused by maternal alloantibodies directed against paternally inherited human platelet alloantigens (HPAs) present on the surface of fetal and neonatal platelets. There are currently no approved… read more here.